Explore/

Most Bought By Hedge Funds

Most Bought By Hedge Funds

10.92k followers30 symbols Watchlist by Yahoo Finance

Follow this list to discover and track the stocks that were bought the most by hedge funds in the last quarter.

30 Symbols

To view complete list, get the Yahoo Finance App

Get the Yahoo Finance app

  • Free real-time data
  • News and price alerts
  • Add and edit holdings
  • Track performance
  • Create multiple watchlists
  • Synopsys (SNPS) to Post Q3 Earnings: What's in the Offing?
    Zacks

    Synopsys (SNPS) to Post Q3 Earnings: What's in the Offing?

    Synopsys' (SNPS) third-quarter fiscal 2019 results are likely to benefit from the increasing uptake of its strong product portfolio. However, Huawei ban remains a major headwind for the company.

  • YUMC or SHAK: Which Is the Better Value Stock Right Now?
    Zacks

    YUMC or SHAK: Which Is the Better Value Stock Right Now?

    YUMC vs. SHAK: Which Stock Is the Better Value Option?

  • Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
    Zacks

    Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day

    Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day

  • Dow, S&P Rebound as Consumers Calm Market
    Zacks

    Dow, S&P Rebound as Consumers Calm Market

    Dow, S&P; Rebound as Consumers Calm Market

  • IQIYI, Inc. Sponsored ADR (IQ) Gains But Lags Market: What You Should Know
    Zacks

    IQIYI, Inc. Sponsored ADR (IQ) Gains But Lags Market: What You Should Know

    In the latest trading session, iQIYI, Inc. Sponsored ADR (IQ) closed at $16.97, marking a +0.24% move from the previous day.

  • BJ's Wholesale Club (BJ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    BJ's Wholesale Club (BJ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    BJ's (BJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • FDA Resets PAD Guidelines: The Road Ahead for Device Makers
    Zacks

    FDA Resets PAD Guidelines: The Road Ahead for Device Makers

    On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.

  • Cardiovascular Systems Set to Present LIBERTY 360 Outcome
    Zacks

    Cardiovascular Systems Set to Present LIBERTY 360 Outcome

    This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).

  • Company News For Aug 15, 2019
    Zacks

    Company News For Aug 15, 2019

    Companies In The News Are: W,M,CAE,MYL

  • Southern Copper's Tia Maria Construction License Suspended
    Zacks

    Southern Copper's Tia Maria Construction License Suspended

    Southern Copper Corporation's (SCCO) Tia Maria copper mine put on hold following protests owing to environmental concerns.

  • Don't Sell Boston Scientific Corporation (NYSE:BSX) Before You Read This
    Simply Wall St.

    Don't Sell Boston Scientific Corporation (NYSE:BSX) Before You Read This

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...

  • NetApp (NTAP) Q1 Earnings & Revenues Beat Estimates, Down Y/Y
    Zacks

    NetApp (NTAP) Q1 Earnings & Revenues Beat Estimates, Down Y/Y

    NetApp's (NTAP) fiscal first-quarter revenue decline reflects weakness in storage business, owing to ongoing macro headwinds.

  • What's in the Cards for iQIYI (IQ) This Earnings Season?
    Zacks

    What's in the Cards for iQIYI (IQ) This Earnings Season?

    iQIYI's (IQ) second-quarter 2019 results are expected to benefit from solid content slate, expanding original content portfolio and partnerships.

  • Thomson Reuters StreetEvents

    Edited Transcript of WTRH earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Waitr Holdings Inc Earnings Call

  • Thomson Reuters StreetEvents

    Edited Transcript of RCII earnings conference call or presentation 8-Aug-19 12:30pm GMT

    Q2 2019 Rent-A-Center Inc Earnings Call

  • Thomson Reuters StreetEvents

    Edited Transcript of MUR earnings conference call or presentation 8-Aug-19 2:00pm GMT

    Q2 2019 Murphy Oil Corp Earnings Call

  • Generic-Drug Giants Accused of Blocking Congressional Probe
    Bloomberg

    Generic-Drug Giants Accused of Blocking Congressional Probe

    (Bloomberg) -- Senator Bernie Sanders and Representative Elijah Cummings are opening an investigation into generic-drug giants Mylan NV and Teva Pharmaceutical Industries Ltd. on allegations of “apparent coordinated obstruction” in failing to provide lawmakers with details about their pricing practices.Sanders, an independent from Vermont who is running for the Democratic nomination for president, and Cummings, a Democrat from Maryland, sent letters to Teva and Mylan as well as closely held Heritage Pharmaceuticals Inc. The letters renewed a 2014 request for the companies to provide documents related to charges of generic-drug price-fixing.The two companies have been at the center of state and federal probes into allegations that generic-drug companies coordinated with one another on setting prices for a range of widely used medications.Lawsuits filed by state attorneys general in 2016 and this year allege a conspiracy among 20 drugmakers to carve up the market and raise prices of more than 100 drugs including commonly prescribed antibiotics as well as medications for reducing cholesterol and controlling seizures. Those actions, authorities allege, cost taxpayers and patients billions of dollars. The prices of some drugs increased by as much as 8,281% between October 2013 and April 2014, according to the lawmakers’ letter made public on Wednesday.The most recent lawsuit included emails from 2014 in which executives at Teva, Mylan and Heritage planned to respond to congressional inquiries with “polite f-u” letters.“Not only did your company’s apparent obstruction undermine our investigation, but it may have caused further harm to patients and health care providers by delaying the discovery of evidence about the companies’ price-fixing,” Sanders and Cummings wrote to the companies on Tuesday. They said withholding or concealing information in a congressional investigation is a violation of federal law.Teva spokeswoman Kelley Dougherty said the company will “continues to cooperate fully with all investigations.”Mylan, which recently announced plans to combine its business with Pfizer Inc.’s unit of older blockbuster medicines, said in a statement that it did not obstruct the 2014 congressional inquiry, and “will continue to cooperate” with investigations.“Mylan respects Congress’s long-standing interest in drug pricing and has worked and will continue to work constructively with Congress to provide it with information relevant to its inquiries,” the company said in a statement.A representative for Pfizer declined to comment. The companies have said they expect their deal to close in mid-2020.A representative for Heritage couldn’t immediately be reached for comment.Mylan fell as much as 8.7% in New York on Wednesday amid a broader stock-market sell-off. Teva’s U.S.-traded stock fell as much as 8.6%; the shares hit their lowest price since 1999 last week when the company set aside $646 million for legal expenses related to its role in the opioid crisis.Probes Hit RoadblocksThe renewed investigation into the drugmakers comes as a federal probe into the generics industry has hit significant obstacles. Over the course of a multiyear Justice Department investigation, only two executives from Heritage Pharmaceuticals have been charged. Both pleaded guilty more than two years ago.The Justice Department will likely bring additional charges soon, Bloomberg reported in July, citing two people familiar with the investigation, though it’s not clear who might be charged. Both people said the probe has encountered challenges, but they said it’s no different from any other complex case. On at least some of the conduct that has come to light, the five-year criminal statute of limitations is set to expire next year.(Updates with comment from Mylan in eighth paragraph.)To contact the reporters on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.net;Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Product Expansion to Aid Applied Materials (AMAT) Q3 Earnings
    Zacks

    Product Expansion to Aid Applied Materials (AMAT) Q3 Earnings

    Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to aid fiscal third-quarter results.

  • Analysts Estimate Pure Storage (PSTG) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Pure Storage (PSTG) to Report a Decline in Earnings: What to Look Out for

    Pure Storage (PSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Should Value Investors Pick Mylan N.V. (MYL) Stock?
    Zacks

    Should Value Investors Pick Mylan N.V. (MYL) Stock?

    Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more.

  • Has Rent-A-Center (RCII) Outpaced Other Consumer Discretionary Stocks This Year?
    Zacks

    Has Rent-A-Center (RCII) Outpaced Other Consumer Discretionary Stocks This Year?

    Is (RCII) Outperforming Other Consumer Discretionary Stocks This Year?

  • Farfetch (FTCH) Catches Eye: Stock Jumps 5.3%
    Zacks

    Farfetch (FTCH) Catches Eye: Stock Jumps 5.3%

    Farfetch (FTCH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Thomson Reuters StreetEvents

    Edited Transcript of PLNT earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Planet Fitness Inc Earnings Call

  • Ciena (CIEN) Gains But Lags Market: What You Should Know
    Zacks

    Ciena (CIEN) Gains But Lags Market: What You Should Know

    Ciena (CIEN) closed at $43.22 in the latest trading session, marking a +0.36% move from the prior day.